Trials / Completed
CompletedNCT02322593
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 711 (actual)
- Sponsor
- Taiho Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-118 plus Oxaliplatin | |
| DRUG | S-1 plus Cisplatin |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2019-02-01
- Completion
- 2020-05-01
- First posted
- 2014-12-23
- Last updated
- 2021-12-20
- Results posted
- 2021-12-20
Locations
6 sites across 2 countries: Japan, South Korea
Source: ClinicalTrials.gov record NCT02322593. Inclusion in this directory is not an endorsement.